

Supplementary Table IB. PICO strategy to identify eligible studies

PICO categories	Inclusion criteria	Exclusion criteria
Population	Female patients Diagnosed with PCOS Randomized controlled trials	Male patients Pregnancy, lactation, those trying to conceive Alternate diagnosis: CAH, hyperprolactinemia, adrenal/ ovarian tumours, other malignancies Non-randomized trials Pre-clinical studies
Intervention	SGLT2 inhibitors alone or in combination	SGLT2 inhibitors not included
Comparator	Placebo or standard therapy	No comparator
Outcome	Efficacy outcomes measures: Change in anthropometric indices, reproductive hormone levels, glycaemic indicators, cardiometabolic parameters Safety outcome measures: Proportion of patients reporting adverse drug events.	Insufficient data on efficacy and safety outcomes